Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab.
Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, Viña L, Orphee R, Hernández O, González C, Fuentes D, Rodríguez V, Charro L, Baro F, Macías A, Pérez A, Morales Y, Subirós N, González B, Ramos M, Rodriquez L, Ballester-Labrada A, Crombet T. Arteaga ME, et al. Among authors: crombet t. Cancer Biol Ther. 2007 Sep;6(9):1390-5. doi: 10.4161/cbt.6.9.4539. Epub 2007 Jun 5. Cancer Biol Ther. 2007. PMID: 17827980
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A. Crombet T, et al. J Clin Oncol. 2004 May 1;22(9):1646-54. doi: 10.1200/JCO.2004.03.089. J Clin Oncol. 2004. PMID: 15117987 Clinical Trial.
Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA, Perera A, Batista JF, Hernández A, Crombet T, Ramos M, Neninger E, Pérez M, Sánchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N. Torres LA, et al. Among authors: crombet t. Nucl Med Commun. 2005 Dec;26(12):1049-57. doi: 10.1097/00006231-200512000-00002. Nucl Med Commun. 2005. PMID: 16264350 Clinical Trial.
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck.
Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T. Rodríguez MO, et al. Among authors: crombet t. Cancer Biol Ther. 2010 Mar 1;9(5):343-9. doi: 10.4161/cbt.9.5.10981. Epub 2010 Mar 20. Cancer Biol Ther. 2010. PMID: 20448462 Clinical Trial.
Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, Catalá M, Griego MG, Martell JA, Luaces PL, Ballesteros J, de-Castro N, Bach F, Crombet T. Solomón MT, et al. Among authors: crombet t. BMC Cancer. 2013 Jun 19;13:299. doi: 10.1186/1471-2407-13-299. BMC Cancer. 2013. PMID: 23782513 Free PMC article. Clinical Trial.
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
Cetina L, Crombet T, Jiménez-Lima R, Zapata S, Ramos M, Avila S, Coronel J, Charco E, Bojalil R, Astudillo H, Bazán B, Dueñas-González A. Cetina L, et al. Among authors: crombet t. Cancer Biol Ther. 2015;16(5):684-9. doi: 10.1080/15384047.2015.1026483. Cancer Biol Ther. 2015. PMID: 25802932 Free PMC article.
58 results